NCT06127095View on ClinicalTrials.gov

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

CompletedOBSERVATIONAL
Enrollment

474

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions
Multiple Sclerosis, Relapsing-Remitting
Trial Locations (1)

02142

Biogen, Cambridge

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT06127095 - A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments | Biotech Hunter | Biotech Hunter